AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02657304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: patients receive only usual care (standard), it's mean: diagnosis with explanation of the disease and benefit of CPAP, entrusts a medical device provider, then an appointment proposed by the doctor or taken by the patient (5 months).
Study NCT02914873 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active surveillance
Description: Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
Study NCT02914873 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active surveillance
Description: Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
Study NCT02342301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing Desk
Description: Participants will be provided with a standing desk for 3 months
Study NCT02342301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Desk
Description: Participants will use a traditional seated desk for 3 months
Study NCT03385889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Spine Mobilization
Description: C1/2 graded mobilizations (Grade III/IV) provided to C1/2 segment on ipsilateral side of unilateral headache. Mobilizations will be completed for 3 sets of 30 seconds.
Study NCT00761696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-926
Description: Oral daily dosing
Study NCT05037019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Women diagnosed with early stage breast cancer are given a single dose of stereotactic body radiation therapy (SBRT) prior to any other treatment in the context of delayed lumpectomy due to the COVID-19 pandemic.
Study NCT03012711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise training
Study NCT02431559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is administered as an IV infusion over 60 ± 5 minutes.
Study NCT03385889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Spine Manipulation
Description: C1/2 manipulation (Grade V) provided to C1/2 segment on ipsilateral side of unilateral headache. The goal of the manipulation technique is to elicit an audible cavitation. If no cavitation is achieved upon the first attempt, a second and final attempt will be completed. No more than two attempts will be utilized per each subject in this allocated group.
Study NCT02431559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: PLD was administered as an IV infusion in accordance with local prescribing information.
Study NCT02431559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motolimod
Description: Motolimod was administered as an SC injection. Within 30 minutes prior to each dose of motolimod, subjects were administered 650-1000 mg acetaminophen by mouth to help mitigate potential adverse events (AEs) commonly associated with the administration of motolimod (e.g., fever, myalgia). On days with concurrent motolimod and durvalumab dosing, motolimod administration occurred 30-60 minutes after the end of the durvalumab infusion. After completion of Phase 1, a protocol amendment was implemented to remove motolimod dosing from the study.
Study NCT02585089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spanish cured-pork ham
Description: Dry-cured ham with reduced salt will be used in order to decrease the sodium intake that could affect blood pressure too. Such ham contains 25% lower salt than similar products on the market (3,7g vs 4,5g/100g).~Volunteers will receive 80g of cured pork ham daily for 28 consecutive days. They can eat the interventional product at any time of the day.
Study NCT02585089 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cooked pork ham
Description: Volunteers will receive 100g of cooked pork ham daily for 28 consecutive days. They can eat the product (placebo product) at any time of the day.
Study NCT02123186 — intervention group
Intervention type: OTHER
Intervention: newborn screening test for SMA
Description: Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
Study NCT00663208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Capsule, Oral, Approximately 182 days from initial dosing
Study NCT03729336 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Catheter for urine collection
Description: In-and-out catheter obtains urine through the urethra.
Study NCT00426283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flovent
Description: 1760 mcg daily
Study NCT00426283 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03422393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: On cycle 1, day 1, patients will initiate venetoclax. The dose of venetoclax will ramp-up from 20 mg PO daily to 400 mg PO daily over a 5 week period.
Study NCT03422393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: During the screening period, patients will continue on ibrutinib at their previous tolerated dose, unless required to stop (e.g.: by a preceding clinical trial).~On cycle 1, day 1, the dose of ibrutinib will be assigned based on the dose cohort. Patients in cohort 1 will receive ibrutinib 420 mg PO daily. Patients in cohort 2 will receive ibrutinib 560 mg PO daily. Cohort 3 will be 840 mg PO daily.
Study NCT00842660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar (gemcitabine)
Description: Gemzar(gemcitabine) Hcl has 2'deoxy-2,2'-difluorouridine monohydrochloride
Study NCT03451877 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: TGFB1 AND LAMA1 GENE POLYMORPHISMS
Description: we evaluated polymorphisms in the LAMA1 (rs2089760) and TGFB1 (rs4803455) genes in children younger than 13 years of age with ≥6 D myopia in an attempt to further elucidate the genetic basis of high myopia.
Study NCT03451877 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: TGFB1 AND LAMA1 GENE POLYMORPHISMS
Description: we evaluated polymorphisms in the LAMA1 (rs2089760) and TGFB1 (rs4803455) genes in children younger than 13 years of age with ≥6 D myopia in an attempt to further elucidate the genetic basis of high myopia.
Study NCT00136084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone
Description: Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
Study NCT00136084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
Description: Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
Study NCT03388138 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A with ketotifen
Description: Etafilcon A with ketotifen
Study NCT03388138 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 1-Day ACUVUE
Description: 1-Day ACUVUE
Study NCT00748475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Study NCT03509675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen suspension 5mg/100ml
Description: Non-Steroidal Anti-inflammatory Topical Rinse will be used for Symptomatic OLP patients.
Study NCT03509675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study NCT03905798 — intervention group
Intervention type: DRUG
Intervention: Lorazepam
Description: The usual dose of lorazepam in adults is 4 mg administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 4 mg may be added but the dose should not exceed 8 mg as the sum of initial and additional doses.~The usual dose of lorazepam in children aged 3 months or older is 0.05 mg/kg (up to 4 mg) administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 0.05 mg/kg may be added but the dose should not exceed 0.1 mg/kg as the sum of initial and additional doses.
Study NCT01257620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Bifidobacterium infantis, 2 capsules (2.0E+9 CFU/capsule) 3 times/day for a total of 1.2E+10 CFU/day for 21 days.
Study NCT01257620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Bifidobacterium infantis, 2 capsules (2.0E+9 CFU/capsule) 3 times/day for a total of 1.2E+10 CFU/day for 21 days.
Study NCT03689361 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: MRI
Description: Routine MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 \*, vascular sequences (AngioRM and TOF) and perfusion).
Study NCT03689361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI control
Description: MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 \*, vascular sequences (AngioRM and TOF) and perfusion)
Study NCT03689361 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: telephone consultation
Description: telephone consultation
Study NCT01539187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VizAblate System
Description: VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy
Study NCT03427723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuvein®400
Description: The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
Study NCT03427723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
Study NCT03146234 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-GPC3 T cells
Description: Self-controlled dose escalation will be applied to the first 3 - 6 subjects enrolled.~Classical 3+3 dose escalation will be applied to subsequent subjects based on the self-controlled dose escalation study.
Study NCT04055597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot and tDCS on-line
Description: Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
Study NCT04055597 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Robot and sham tDCS
Description: Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
Study NCT01064895 — intervention group
Intervention type: DEVICE
Intervention: Benephit catheter for Targeted Renal Therapy
Description: Local physician-specified agent delivery to the kidneys bilaterally via the renal arteries using the Benephit infusion system.
Study NCT01885091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinerase
Study NCT02313610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qinbudan
Description: Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice
Study NCT02313610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qinbudan Placebo
Description: Qinbudan Placebo was the same as therapeutic drug in package,shape,size.
Study NCT00743912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifaximin
Description: 550 mg TID
Study NCT03810066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: All patients will be treated with osimertinib 80 mg/d for one cycle (28 days).
Study NCT02848001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90009
Description: CC-90009
Study NCT00835393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole Sodium 40 mg delayed-release tablets
Description: 1 x 40 mg
Study NCT00835393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROTONIX® 40 mg delayed-release tablets.
Description: 1 x 40 mg
Study NCT03337061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Mindfulness Meditation delivered through a mobile application
Study NCT01088477 — intervention group
Intervention type: OTHER
Intervention: Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol
Description: In patients with acquired antihormonal resistance, eligible for estrogen therapy, a FES-PET scan will be made to determine FES-PET tumor uptake (which corresponds to estrogen receptor expression levels). Immediately after the FES-PET scan, all patients will start with a standard accepted dose of 2mg estradiol TID. Therapy response will be monitored by regular follow-up. RECIST criteria and clinical benefit will be used as criteria. In case of disease progression before end of the study period, estradiol treatment will be stopped.
Study NCT03438838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Heller's myotomy
Description: Laparoscopic Heller's myotomy:~Anterior wall of esophagus is exposed by opening peritoneum and minimal dissection of fat over it. Myotomy is started at 2 cm above the esophago- gastric junction. Initial plane is created using dissector and further muscles are split using pair of dissector or bowel holding forceps for length of 7 to 8 cm with 2 cm over stomach
Study NCT03102918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.
Study NCT03102918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo over a 6-week treatment period.
Study NCT01762943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: All subjects will receive one IM injection (3.75 mg) each month for four months.
Study NCT01762943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized estradiol
Description: All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.
Study NCT01762943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.
Study NCT02674620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Patients are treated with progressive exercise
Study NCT00663208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
Study NCT03438838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Fundoplication
Description: The Fundus was sutured with 3 stitches on either side of the esophagus to right and left crus of diaphragm using ethibond(1-0) beside intervening stitch over esophagus. Width of fundoplication is kept approximately at 2cm. The proximal short gastric vessels were divided only if the fundus is insufficiently mobile
Study NCT02054507 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Cognitive evaluation (Wechsler IV tests)
Description: Children born prematurely in a level III referral Center will undergo psychometric evaluation at 8 to 11 years of age by routine test (WISC IV). The relationship between cognitive scores and neonatal characteristics will be determined and compared with the results of schoolmate control children, born at term.
Study NCT04498793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: On Day 1 of the last seven cycles in the neoadjuvant and each cycle in the adjuvant phases of the study for a total of 21 cycles; intravenous (IV) infusion.
Study NCT04236986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: LPS will be administered intravenously (1.0ng/kg; IV)
Study NCT01882166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostimon
Study NCT01882166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: puregon
Study NCT05804695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic TMJ disc repositioning under GA
Description: a surgical procedure used to treat Tempro- mandibular disc displacement using arthroscope.
Study NCT04756661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: 100 mcg of Carbetocin intravenous injection
Study NCT04756661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 10 IU oxytocin IV drip
Study NCT04756661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 mcg rectal
Study NCT04989543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: vaginal swabs
Description: Nugent score: Vaginal swabbing with the dry swab, make two smears on slides.~Cytobacteriological examination: swabbing at the exo-endocrine junction using the swab~Evaluation of the vaginal microbiota: swabbing at the exo-endocrine junction using the swab
Study NCT02561429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPT
Description: SPT of histamine concentration 1, 5 and 10 mg/ml
Study NCT03575208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B immune globulin (HBIg)
Description: HBIg 20,000 U/L iv. Dosing interval will depend on anti-HBs levels.
Study NCT03575208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa (pegIFN)
Description: peginterferon alfa-2a 180 mcg weekly for 24 weeks
Study NCT03575208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa (pegIFN)
Description: peginterferon alfa-2a 180 mcg weekly for 24 weeks
Study NCT04127773 — intervention group
Intervention type: DEVICE
Intervention: oro gastric tube
Description: According to clinical need, an orogastric tube will be inserted at birth using the group method in VLBW infants in whom an umbilical catheter has been placed. An X-ray chest will be performed according to routine clinical practice to assess the position of the umbilical catheter. On the same X-ray the position of the gastric tube will be assessed by a radiologist blinded to the method used for orogastric tube placement.
Study NCT03911830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise followed cold water immersion
Description: Rehabilitation program of 17 sessions with 30 minutes of exercise followed by 15 minutes of submerged recovery at 17 ° C (3 sessions per week / 6 weeks).
Study NCT01487525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double leg press with partial blood flow restriction
Description: double isotonic and isokinetic leg press extension with application of partial blood flow restriction to the upper leg
Study NCT01487525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Double leg press without partial blood flow restriction
Description: double isotonic and isokinetic leg press extension without application of partial blood flow restriction to the upper leg
Study NCT04233294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
Study NCT04233294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
Study NCT04233294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
Study NCT01568567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuteri DSM 17938
Description: One stick pack in the morning and one stick pack afternoon/evening for 28 days.
Study NCT01568567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus Reuteri DSM 17938
Description: One stick pack in the morning and one stick pack afternoon/evening for 28 days.
Study NCT00096629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human prostate-specific membrane antigen plasmid DNA vaccine
Study NCT00096629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mouse prostate-specific membrane antigen plasmid DNA vaccine
Study NCT04447040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/naproxen sodium Dose A
Description: Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
Study NCT04447040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/naproxen sodium Dose B
Description: Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.